San Francisco, 05 February, Antibody Drug Conjugates Market Size, Share
& Trends Analysis Report By Application (Brain Tumor, Blood, Breast,
Ovarian, Lung Cancer), By Technology (Cleavable, Non-cleavable Linker), And
Segment Forecasts, 2019 – 2025.
The global antibody drug conjugate market size is expected to reach
USD 9.93 billion by 2025, according to a new report by Grand View Research, Inc.
it is projected to expand at a CAGR of 25.9% over the forecast period.
Increasing incidence of cancer coupled with growing geriatric population are
likely to drive the market for Antibody-Drug Conjugates (ADC). Furthermore,
major technological advancements are also contributing to drive the growth.
According to the World Health Organization (WHO), the number of people aged 65
years and above, is projected to reach 16% of the total population by 2050 from
7% in 2000. Aging has become a substantial risk factor for numerous diseases
including cancer and others. Hence, the growing geriatric population is
expected to drive growth of the market over the forecast period.
Until 2018, four ADCs were
available in the market, namely, Adcetris, Kadcyla, Besponsa, and Mylotarg. Due
to appropriate targeting and improved technology, ADCs have been gaining a lot
of attention from both small and large pharmaceutical companies. Currently
there are more than 50 ADCs in clinical trials and it has been projected that
during the forecast period three to four ADCs will be commercialized in the
area of refractory Hodgkin lymphoma, glioblastoma, small cell lung cancer,
breast cancer, and ovarian cancer. It has been observed that the maximum number
of clinical trials are being conducted for lymphoma.
Seattle Genetics and Roche are leading the antibody drug
conjugate market in terms of market share. Until 2017 only two ADCs were
commercially available-Adcetris by Seattle Genetics and Kadcyla by Roche.
Recently, two more Pfizer’s products were approved to be marketed for acute
myeloid leukaemia and acute lymphoblastic leukaemia. Hence, it has been
estimated that over the forecast period, Pfizer is anticipated to gain a
significant market share.
Access Full Research
Report On Antibody Drug
Conjugates Market Analysis:
Further key findings from the report suggest:
·
Breast cancer was the largest
segment in 2017 and is likely to witness a significant growth over the forecast
period due to the factors such as availability of Kadcyla and high prevalence
of breast cancer
·
Cleavable linker is expected to
witness the fastest growth over the forecast period as the maximum product in
the pipeline contains cleavable linkers. In addition, in 2017 two new
products-Besponsa and Mylotarg were approved in the market
·
In 2017, North America was the
largest revenue generating region in the antibody-drug conjugates market. It is
the most well-established regions in terms of patient awareness and usage of
ADCs and makes up most of the existing market
·
The players operating in this
space are F. Hoffmann-La Roche Ltd; Seattle Genetics, Inc.; Pfizer Inc.; Takeda
Pharmaceutical Company Limited; AbbVie Inc.; Immunomedics; and ImmunoGen Inc.
·
Market players are adopting
strategies, such as introducing technologically advanced products,
collaborations, and geographic expansions to increase their market share. For
instance, Seattle Genetics collaborated with Takeda for developing brentuximab
vedotin (Adcetris) for refractory/relapsed Hodgkin lymphoma.
Browse More Reports Of This Category By
Grand View Research At: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the
global antibody drug conjugate market on the basis of application, technology,
and region:
Antibody Drug Conjugate
Application Outlook (Revenue, USD Million, 2014 - 2025)
·
Blood Cancer
o
Leukemia
o
Lymphoma
·
Breast Cancer
·
Ovarian Cancer
·
Lung Cancer
·
Brain Tumor
Antibody Drug Conjugate
Technology Outlook (Revenue, USD Million, 2014 - 2025)
·
Cleavable Linker
·
Non-cleavable Linker
Antibody Drug Conjugate
Regional Outlook (Revenue, USD Million, 2014 - 2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
U.K.
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
·
Middle East & Africa
o
South Africa
Access Full
Press Release of this Report: www.grandviewresearch.com/press-release/global-antibody-drug-conjugates-market
About Grand
View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com/
No comments:
Post a Comment